About Quest Diagnostics Incorporated
https://www.questdiagnostics.comQuest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
CEO
James E. Davis
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2005-06-21 | Forward | 2:1 |
| 2001-06-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 669
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Jefferies
Buy
Leerink Partners
Outperform
Mizuho
Outperform
Barclays
Equal Weight
Evercore ISI Group
In Line
Piper Sandler
Neutral
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:14.25M
Value:$2.66B
BLACKROCK INC.
Shares:10.06M
Value:$1.88B
BLACKROCK, INC.
Shares:10M
Value:$1.87B
Summary
Showing Top 3 of 1,360
About Quest Diagnostics Incorporated
https://www.questdiagnostics.comQuest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.82B ▲ | $563M ▲ | $245M ▼ | 8.7% ▼ | $2.18 ▼ | $547M ▼ |
| Q2-2025 | $2.76B ▲ | $505M ▼ | $282M ▲ | 10.21% ▲ | $2.51 ▲ | $596M ▲ |
| Q1-2025 | $2.65B ▲ | $517M ▲ | $220M ▼ | 8.3% ▼ | $1.97 ▼ | $488M ▼ |
| Q4-2024 | $2.62B ▲ | $497M ▲ | $222M ▼ | 8.47% ▼ | $1.98 ▼ | $507M ▲ |
| Q3-2024 | $2.49B | $481M | $226M | 9.08% | $2.01 | $479M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $432M ▲ | $16.2B ▲ | $8.82B ▲ | $7.26B ▲ |
| Q2-2025 | $319M ▲ | $15.97B ▲ | $8.62B ▼ | $7.23B ▲ |
| Q1-2025 | $188M ▼ | $15.8B ▼ | $8.75B ▼ | $6.93B ▲ |
| Q4-2024 | $549M ▼ | $16.15B ▲ | $9.26B ▲ | $6.78B ▼ |
| Q3-2024 | $764M | $16.09B | $9.17B | $6.81B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $259M ▼ | $563M ▲ | $-201M ▼ | $-247M ▲ | $113M ▼ | $419M ▼ |
| Q2-2025 | $296M ▲ | $544M ▲ | $-124M ▼ | $-293M ▲ | $131M ▲ | $436M ▲ |
| Q1-2025 | $235M ▲ | $314M ▼ | $-115M ▲ | $-561M ▼ | $-361M ▼ | $197M ▼ |
| Q4-2024 | $222M ▼ | $464M ▲ | $-502M ▲ | $-170M ▼ | $-215M ▼ | $341M ▲ |
| Q3-2024 | $237M | $356M | $-1.63B | $1.77B | $493M | $250M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Diagnostic Information Services Business | $2.56Bn ▲ | $2.59Bn ▲ | $2.70Bn ▲ | $2.75Bn ▲ |
CEO
James E. Davis
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2005-06-21 | Forward | 2:1 |
| 2001-06-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 669
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Jefferies
Buy
Leerink Partners
Outperform
Mizuho
Outperform
Barclays
Equal Weight
Evercore ISI Group
In Line
Piper Sandler
Neutral
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:14.25M
Value:$2.66B
BLACKROCK INC.
Shares:10.06M
Value:$1.88B
BLACKROCK, INC.
Shares:10M
Value:$1.87B
Summary
Showing Top 3 of 1,360